Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)
Status: | Completed |
---|---|
Conditions: | Renal Impairment / Chronic Kidney Disease |
Therapuetic Areas: | Nephrology / Urology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/14/2018 |
Start Date: | January 2015 |
End Date: | February 2018 |
Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
1. To examine two main predictor variables independently and then jointly in stratified and
multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient
mortality, and the composite, as well as the outcomes of 30 day rehospitalization or
death, and finally for the days out of hospital and alive adjusted to person-year of
time
1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
2. Thakar Acute Renal Failure (ARF) score (1 to 17)
2. To examine the interrelationships between time in days between angiogram and surgery and
the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient
mortality, and the composite, as well as the outcomes of 30 day rehospitalization or
death, and finally for the days out of hospital and alive adjusted to person-year of
time
1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
2. Thakar Acute Renal Failure (ARF) score (1 to 17)
2. To examine the interrelationships between time in days between angiogram and surgery and
the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Background: Despite advances in cardiac surgical techniques, modern anesthesia, and
adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI)
remains a frequent and important complication. With advancing age and more severe
comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g.
Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that
resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy
(RRT), and are associated major adverse cardiac events with early and later mortality. Mehta
and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time
between the diagnostic coronary angiogram and the subsequent surgery. This suggested that
superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial
insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and
coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3
days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating
CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et
el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores
could not be computed due to lack of information and those that could have unstable point
estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts
to improve quality of care have not been applied in a widespread manner to cardiac surgical
cases. Thus we propose to evaluate these key concepts in a large dataset which captures
important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and
associated major adverse renal and cardiac events (MARCE) including the need for RRT,
myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death.
We aim to derive a practical approach in determining the optimal waiting period from the time
of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received
iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown
to have the lowest risk of CI-AKI.
Specific Aims:
1. To examine two main predictor variables independently and then jointly in stratified and
multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient
mortality, and the composite, as well as the outcomes of 30 day rehospitalization or
death, and finally for the days out of hospital and alive adjusted to person-year of
time
1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
2. Thakar Acute Renal Failure (ARF) score (1 to 17)
2. To examine the interrelationships between time in days between angiogram and surgery and
the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who
have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
1. Use of contrast agent other than IOCM with the preoperative angiogram
2. Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
3. Operations where there is implantation of mechanical assist devices or cardiac
transplant
Measurements:
1. CI-AKI will be assessed by several methods during the period from angiography to cardiac
surgery:
1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum
creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum
creatinine within seven days after surgery
2. Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum
creatinine from baseline to peak
3. Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from
baseline to peak
4. Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from
baseline to peak
2. CSA-AKI will be defined by several methods:
1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum
creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum
creatinine within seven days after surgery
2. Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in
serum creatinine from baseline to peak
3. Conventional singular derived from CI-AKI definition of ≥25% rise in serum
creatinine from baseline to peak
4. Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum
creatinine from baseline to peak
3. MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure,
hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
4. RRT will include at least one session of peritoneal dialysis ultrafiltration,
hemodialysis, or other form of extracorporeal blood purification
5. All-cause hospitalization, emergency room, and observation unit visits at 30 days, and
one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and
Research (DFWHC) connected a regional enterprise master person index (REMPI) database
6. All-cause mortality will be reported as inpatient, 30-day, and one-year
7. Days out of the hospital and alive will be derived as the converse of death and
hospitalized days and will be adjusted to 100 PY of time exposure
8. Baseline eGFR will be calculated using the CKD-EPI formula
GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159
[if black]
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is
-0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and
max indicates the maximum of Scr/κ or 1.
9. Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time,
coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI
will be reported in baseline characteristics and considered as candidates for
multivariable models
adjunctive medical therapies, cardiac-surgery associated acute kidney injury (CSA-AKI)
remains a frequent and important complication. With advancing age and more severe
comorbidities present in patients undergoing cardiac surgery, multivariate scores (e.g.
Thakar Acute Renal Failure [ARF] score) would anticipate future higher rates of CSA-AKI that
resolve, lead to progressive chronic kidney disease (CKD), require renal replacement therapy
(RRT), and are associated major adverse cardiac events with early and later mortality. Mehta
and colleagues in a study of 2441 cases suggested that CSA-AKI was associated with the time
between the diagnostic coronary angiogram and the subsequent surgery. This suggested that
superimposed risk of contrast-induced AKI (CI-AKI) followed by cardiac surgery was a serial
insult to the kidneys producing the clinical syndrome of CSA-AKI. However, Andersen and
coworkers, in a study of 285 consecutive patients concluded that cardiac surgery within 1-3
days of coronary angiography was safe and not associated with CSA-AKI. Attempts at evaluating
CSA-AKI risk prediction models have been limited by small sample sizes. For example, Kiers et
el attempted to evaluate 8 CSA-AKI risk models in 1388 patients and found several scores
could not be computed due to lack of information and those that could have unstable point
estimates for C-statistics and other measures. As a result, CSA-AKI risk scores and attempts
to improve quality of care have not been applied in a widespread manner to cardiac surgical
cases. Thus we propose to evaluate these key concepts in a large dataset which captures
important clinical events such as CI-AKI and type of contrast used followed by CSA-AKI and
associated major adverse renal and cardiac events (MARCE) including the need for RRT,
myocardial infarction, stroke, heart failure, hospitalizations (cardiac or renal) and death.
We aim to derive a practical approach in determining the optimal waiting period from the time
of angiography to cardiac surgery according to risk for CSA-AKI in subjects who have received
iso-osmolar contrast media (IOCM) with preoperative angiography, as that agent has been shown
to have the lowest risk of CI-AKI.
Specific Aims:
1. To examine two main predictor variables independently and then jointly in stratified and
multivariate analyses for the outcomes of CSA-AKI, MARCE, need for RRT, and inpatient
mortality, and the composite, as well as the outcomes of 30 day rehospitalization or
death, and finally for the days out of hospital and alive adjusted to person-year of
time
1. Days from coronary angiogram performed with IOCM to cardiac surgery (1, 2, 3, etc)
2. Thakar Acute Renal Failure (ARF) score (1 to 17)
2. To examine the interrelationships between time in days between angiogram and surgery and
the ARF Score with the Society of Thoracic Surgery (STS) Risk score for mortality
Methods
Study Design: Retrospective cohort
Subjects: Using the Texas Quality Initiative cardiothoracic surgery database, patients who
have recorded one preoperative and at least one postoperative serum creatinine (mg/dl).
Excluded Cases
1. Use of contrast agent other than IOCM with the preoperative angiogram
2. Preoperative use of ventricular assist devices and intraaortic balloon counterpulsation.
3. Operations where there is implantation of mechanical assist devices or cardiac
transplant
Measurements:
1. CI-AKI will be assessed by several methods during the period from angiography to cardiac
surgery:
1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum
creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum
creatinine within seven days after surgery
2. Conventional composite CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in serum
creatinine from baseline to peak
3. Conventional singular CI-AKI definition of ≥25% rise in serum creatinine from
baseline to peak
4. Conventional singular CI-AKI definition of ≥0.5 mg/dl rise in serum creatinine from
baseline to peak
2. CSA-AKI will be defined by several methods:
1. Kidney Disease International Global Initiative (KDIGO) as a rise in serum
creatinine ≥0.3 mg/dl within 48 hours of surgery or ≥1.5 X baseline serum
creatinine within seven days after surgery
2. Conventional composite derived from CI-AKI definition of ≥25% or ≥0.5 mg/dl rise in
serum creatinine from baseline to peak
3. Conventional singular derived from CI-AKI definition of ≥25% rise in serum
creatinine from baseline to peak
4. Conventional singular derived from CI-AKI definition of ≥0.5 mg/dl rise in serum
creatinine from baseline to peak
3. MARCE will be the composite of RRT, myocardial infarction, stroke, heart failure,
hospitalizations for cardiac reasons, hospitalization for renal reasons, and death
4. RRT will include at least one session of peritoneal dialysis ultrafiltration,
hemodialysis, or other form of extracorporeal blood purification
5. All-cause hospitalization, emergency room, and observation unit visits at 30 days, and
one-year will be obtained from the Dallas-Fort Worth Hospital Council Education and
Research (DFWHC) connected a regional enterprise master person index (REMPI) database
6. All-cause mortality will be reported as inpatient, 30-day, and one-year
7. Days out of the hospital and alive will be derived as the converse of death and
hospitalized days and will be adjusted to 100 PY of time exposure
8. Baseline eGFR will be calculated using the CKD-EPI formula
GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159
[if black]
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is
-0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and
max indicates the maximum of Scr/κ or 1.
9. Clinical factors: age, diabetes, Hb, heart failure, operative variables (bypass time,
coronary bypass with valve surgery, on-pump, off-pump) and other predictors of CSA-AKI
will be reported in baseline characteristics and considered as candidates for
multivariable models
Inclusion Criteria:
1. Cardiac surgery with or without cardiac valve surgery
2. At least one baseline and postoperative serum creatinine (mg/dl)
Exclusion Criteria:
1. Use of contrast agent other than IOCM with the preoperative angiogram
2. Preoperative use of ventricular assist devices and intraaortic balloon
counterpulsation.
3. Operations where there is implantation of mechanical assist devices or cardiac
transplant
We found this trial at
1
site
Dallas, Texas 75226
Principal Investigator: Peter A McCullough, MD, MPH
Phone: 214-820-7997
Click here to add this to my saved trials